Overview

Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RA

Status:
Unknown status

Trial end date:
2020-03-30

Target enrollment:

Participant gender:

Summary

Phase 3b, single arm, single site simplification study of HIV-1 infected patients with virological suppression under the combination of Lamivudine (150 mg BID) plus Raltegravir (400 mg BID) switching to Lamivudine (300 mg QD) plus Raltegravir (1200 mg QD): Roll-over study of the RALAM clinical trial (NCT02284035)

Phase:

Phase 3

Details

Lead Sponsor:

David Garcia Cinca

Collaborators:

Fundació Clínic per a la Recerca Biomèdica
Fundacion Clinic per a la Recerca Biomédica

Treatments:

Lamivudine
Raltegravir Potassium